glp 1 patents GLP-1 Patent Landscape: Who Leads the Innovation Race Pharma or Food? The Heavy Price of GLP-1

Key Evidence in the Litigation A 2023 study published in JAMA Internal Medicine linked GLP-1 drugs to a significantly increased risk of gastroparesis Ophthalmologists have reported a rise in NAION cases among Ozempic users, prompting calls for label updates The FDAs FAERS database shows thousands of complaints involving gastrointestinal and ocular complications Internal company documents obtained through discovery may reveal early knowledge of these risks Novo Nordisk continues to deny wrongdoing, stating that Ozempic is safe when used as directed

Pancreatic Health GLP-1 medications stimulate your pancreas to release insulin

A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots

Final word My biggest advice to manufacturers would be to not treat this as an elimination of spend, says Pattni

In mid-September, Lemme debuted its GLP-1 Daily supplement, priced at $90 for a one-month supply without a subscription